eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2020
vol. 71
 
Share:
Send email
Share:
abstract:
Original paper

The importance of IDH1, ATRX and WT-1 mutations in glioblastoma

Gülsün Gülten
1
,
Nagİhan Yalçın
1
,
Bahar Baltalarlı
2
,
Gamze Gököz Doğu
3
,
Ferİdun Acar
4
,
Yücel Doğruel
4

  1. Pathology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
  2. Radiation Oncology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
  3. Medical Oncology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
  4. Brain Surgery Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
Pol J Pathol 2020; 71 (2): 127-137
DOI: https://doi.org/10.5114/pjp.2020.97020
Online publish date: 2020/07/21
View full text Get citation
 
PlumX metrics:
Numerous genetic pathways associated with glioblastoma development have been identified. In this study, we investigated the prognostic significance of IDH1 and ATRX mutations and WT-1 and p53 expression in glioblastomas and that of surgical methods, radiotherapy and chemotherapy. 83 patients with glioblastomas were retrospectively evaluated. Immunohistochemical analysis was performed for IDH1, ATRX and WT-1 expression. Tumour cells were positive for IDH1 in 9.6% of the patients. In 4.8% of the patients, loss of ATRX expression was observed in tumour cells; 86.7% of the patients were WT-1 positive, and 12.05% of the patients were p53 positive. No statistically significant difference was found in the progression-free and overall survival according to IDH1, ATRX, WT-1 and p53 expression. There was a statistically significant difference in the progression-free and overall survival according to the radiotherapy status. There was a statistically significant difference in the overall survival according to the chemotherapy status. There was no statistically significant difference in the progression-free and overall survival according to the surgical method. IDH1 and ATRX mutations, p53 overexpression and WT-1 expression alone did not have a significant effect on the prognosis of patients with glioblastoma; however, radiotherapy and chemotherapy had a positive effect on survival.
keywords:

glioblastoma, immunohistochemistry, IDH1, ATRX, WT-1
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.